Dr. Lee on the Rationale for Evaluating Telaglenastat in RCC

Publication
Video
Supplements and Featured PublicationsUtilizing Tumor Metabolism in Solid Malignancies
Volume 1
Issue 1

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.

Chung-Han Lee, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale for evaluating telaglenastat in renal cell carcinoma (RCC).

Research regarding the natural history of RCC has shown that the disease appears to be a metabolic malignancy, says Lee. This means that many different metabolic alterations affect disease pathogenesis in RCC. 

Several preclinical studies ​have demonstrated that almost all of the molecules within the tricarboxylic acid cycle rely on glutamine​, which play​s an important role in the synthesis of fatty acid​s, Lee adds.

Notably, telaglenastat is able to block cells from utilizing glutamine​, explains Lee.

As such, this agent is being further evaluated in multiple clinical trials to determine if patients can derive benefit from an altered metabolism, Lee concludes

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD